As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive ...

Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...

CHOICE-2 supports intra-arterial alteplase after successful reperfusion ...

Rochester, MN - Starting a 72-hour infusion of nesiritide (Natrecor, Scios/Johnson & Johnson) after successful MI reperfusion therapy apparently suppressed aldosterone levels and may have had a ...

Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from two independent Phase 2 clinical trials with its novel stroke drug LT3001 (Odatroltide). LT3001 is a first-in-class ...

Longer door-in-door-out times are associated with adverse therapy and complication outcomes for patients with acute ischemic stroke.

Mesenchymal stromal cells (MSCs) were cultured on microcarriers in 3D rotating bioreactors and primed with ginsenoside Rg1 to enhance cell proliferation. Artificial cell-derived vesicles (ACDVs) from ...

Ischemic heart disease is the leading cause of death globally, causing approximately 9 million deaths annually. Currently, reperfusion therapy (such as thrombolysis or interventional procedures) is ...

Alternative model systems to study ischemia-reperfusion are needed to support a wide range of disease-related investigations in the life sciences. Ischemia and reperfusion are relevant to many disease ...

Bone marrow-derived allogeneic stem cell therapy shortly after ischemic stroke did not improve outcomes at 90 days, a phase II/III randomized clinical trial known as TREASURE found. However, ...